Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Astellas
Astellas
FDA starts review of Padcev/Keytruda for bladder cancer
FDA starts review of Padcev/Keytruda for bladder cancer
Pharmaphorum
Merck
Astellas
Seagen
Padcev
bladder cancer
FDA
priority review
Flag link:
Astellas builds case for menopause drug fezolinetant
Astellas builds case for menopause drug fezolinetant
Pharmaphorum
Astellas
menopause
fezolinetant
Flag link:
Xtandi cleared by FDA for earlier-stage prostate cancer
Xtandi cleared by FDA for earlier-stage prostate cancer
Pharmaphorum
Pfizer
Astellas
Xtandi
prostate cancer
FDA
Flag link:
Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff
Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff
Fierce Biotech
Astellas
Propella Therapeutics
M&A
JNJ
Zytiga
prostate cancer
Flag link:
Astellas Sees Path Forward for Gene Therapy Despite Four Patient Deaths
Astellas Sees Path Forward for Gene Therapy Despite Four Patient Deaths
BioSpace
Astellas
AT132
patient deaths
FDA
X-linked myotubular myopathy
Flag link:
Astellas’ Izervay reduces GA lesion growth in Phase III trial
Astellas’ Izervay reduces GA lesion growth in Phase III trial
Clinical Trials Arena
Astellas
Izervay
geographic atrophy
age-related macular degeneration
clinical trials
Flag link:
A New Drug For Menopausal Hot Flashes, Veozah, Faces Access Challenges
A New Drug For Menopausal Hot Flashes, Veozah, Faces Access Challenges
Forbes
Astellas
hot flashes
menopause
Veozah
access
Flag link:
ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer
ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer
Fierce Pharma
Seagen
Astellas
Merck
Padcev
Keytruda
bladder cancer
ESMO
Flag link:
Astellas rolls out national Veozah campaign for treating menopause symptoms
Astellas rolls out national Veozah campaign for treating menopause symptoms
Medical Marketing and Media
Astellas
Veozah
menopause
hot flashes
TV ads
DTC ads
Flag link:
Patient Death Likely from Virus Used to Deliver Gene-Editing Therapy: NEJM Study
Patient Death Likely from Virus Used to Deliver Gene-Editing Therapy: NEJM Study
BioSpace
NEJM
clinical trials
Duchenne Muscular Dystrophy
patient deaths
Astellas
Pfizer
Flag link:
Astellas Withdrew Its Inflation Reduction Act Lawsuit—Will Other Companies Follow?
Astellas Withdrew Its Inflation Reduction Act Lawsuit—Will Other Companies Follow?
BioSpace
Astellas
legal
Inflation Reduction Act
Flag link:
Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo
Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo
BioSpace
Merck
Seagen
Astellas
urothelial cancer
clinical trials
bladder cancer
Padcev
Keytruda
Flag link:
Taysha ends work on gene therapy after Astellas walks away, FDA requests randomized trial
Taysha ends work on gene therapy after Astellas walks away, FDA requests randomized trial
Fierce Biotech
Astellas
Taysha Gene Therapies
gene therapy
FDA
Flag link:
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of Izervay for Geographic Atrophy
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of Izervay for Geographic Atrophy
PR Newswire
Astellas
clinical trials
Izervay
geographic atrophy
Flag link:
EU clears review of Xtandi in earlier-stage prostate cancer
EU clears review of Xtandi in earlier-stage prostate cancer
Pharmaphorum
EMA
Europe
Astellas
Pfizer
prostate cancer
Xtandi
Flag link:
Astellas withdraws lawsuit challenging Medicare drug price negotiation plans
Astellas withdraws lawsuit challenging Medicare drug price negotiation plans
Reuters
Astellas
Medicare
prostate cancer
Xtandi
drug pricing
Inflation Reduction Act
Flag link:
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
BioSpace
patent cliff
patents
Takeda
Vyvanse
Pfizer
Eraxis
JNJ
Stelara
Merck
Isentress
Eiger Pharmaceuticals
Zokinvy
Astellas
Myrbetriq
Novartis
Entresto
Amgen
Otzela
Flag link:
The 10 drugs that CMS might wrangle into negotiations
The 10 drugs that CMS might wrangle into negotiations
Beckers Hospital Review
CMS
Medicare
drug pricing
Bristol Myers Squibb
Janssen
Merck
Pfizer
Amgen
Boehringer Ingelheim
Pharmacyclics
AstraZeneca
Astellas
GSK
Flag link:
Astellas to Open New Life Sciences Facility in DivcoWest's Cambridge Crossing Neighborhood
Astellas to Open New Life Sciences Facility in DivcoWest's Cambridge Crossing Neighborhood
PR Newswire
Astellas
Cambridge MA
R&D
Flag link:
Iveric drug approved for type of vision loss as rival’s safety draws scrutiny
Iveric drug approved for type of vision loss as rival’s safety draws scrutiny
BioPharma Dive
Iveric Bio
geographic atrophy
FDA
Izervay
Astellas
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »